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Transferrin receptor (TfR) is a dimeric cell surface
protein that binds both the serum iron transport protein
transferrin (Fe-Tf) and HFE, the protein mutated in pa-
tients with the iron overload disorder hereditary hemo-
chromatosis. HFE and Fe-Tf can bind simultaneously to
TfR to form a ternary complex, but HFE binding to TfR
lowers the apparent affinity of the Fe-Tf/TfR interac-
tion. This apparent affinity reduction could result from
direct competition between HFE and Fe-Tf for their
overlapping binding sites on each TfR polypeptide
chain, from negative cooperativity, or from a combina-
tion of both. To explore the mechanism of the affinity
reduction, we constructed a heterodimeric TfR that con-
tains mutations such that one TfR chain binds only HFE
and the other binds only Fe-Tf. Binding studies using a
heterodimeric form of soluble TfR demonstrate that TfR
does not exhibit cooperativity in heterotropic ligand
binding, suggesting that some or all of the effects of HFE
on iron homeostasis result from competition with Fe-Tf
for TfR binding. Experiments using transfected cell
lines demonstrate a physiological role for this competi-
tion in altering HFE trafficking patterns.
Hereditary hemochromatosis is a prevalent genetic disorder
characterized by a defect in a checkpoint of iron homeostasis
resulting in the absorption of dietary iron beyond the body’s
needs. If left untreated, hereditary hemochromatosis results in
the deposit of iron primarily in the liver, heart, pancreas, and
parathyroid and pituitary glands, leading to pathologies such
as arthritis, liver cancer, diabetes, cardiomyopathy, and bronz-
ing of skin (1, 2). Positional cloning revealed that most hered-
itary hemochromatosis patients carry mutations in the gene
coding for a protein called HFE (3). HFE is a membrane protein
homologous to class I major histocompatibility complex pro-
teins (3), which present antigenic peptides to T lymphocytes
(4). Like class I major histocompatibility complex molecules
and most other class I homologs, HFE is a heterodimer in
which a membrane-bound heavy chain associates nonco-
valently with the light chain 2-microglobulin (3). Most hered-
itary hemochromatosis patients are homozygous for a mutation
that converts residue 260 of the mature HFE protein from
cysteine to tyrosine (3), preventing proper folding, 2-micro-
globulin association, and cell surface expression and eliminat-
ing its effects on cellular iron levels (5–7).
A potential link between HFE and the regulation of iron
homeostasis was established by the observation that HFE
binds to transferrin receptor 1 (TfR)1 (8, 9), a homodimeric cell
surface glycoprotein that serves as the receptor for iron-loaded
transferrin (Fe-Tf) (10). Each chain of the TfR homodimer
contains an 640-residue ectodomain, a glycosylated stalk re-
gion, a membrane-spanning segment, and an N-terminal cyto-
plasmic domain containing a YTRF endosomal sorting signal.
This motif serves as a signal for endocytosis and transport back
to the cell surface through recycling endosomes (11–13). The
extracellular domain of TfR forms a high affinity complex with
circulating Fe-Tf and transports it to acidic endosomes. At the
low pH of endosomes (pH 6.5), TfR assists in the release of
iron from Fe-Tf (14, 15). The iron-free form of Tf (apo-Tf)
remains bound to TfR inside acidic endosomes and is recycled
to the cell surface, where apo-Tf dissociates at the slightly basic
pH of the blood (16).
TfR can form a number of complexes with HFE and Fe-Tf
(Fig. 1). TfR homodimers bind two Fe-Tf molecules to form
Fe-TfTfR complexes with 2:1 ligand/receptor stoichiometry
(17, 18). Soluble TfR homodimers also bind two HFE molecules
to form 2:1 HFETfR complexes (19, 20), although 1:1 HFETfR
complexes can be found in solution using soluble forms of HFE
and TfR (18, 20). When all three proteins are present,
HFETfRFe-Tf ternary complexes are observed in solution (18)
and in lysates from HFE-transfected HeLa cells (21, 22). Com-
petition (23), mutagenesis (20, 24), time-resolved x-ray foot-
printing (25), and electron microscopy studies (26) demonstrate
that Fe-Tf and HFE compete for overlapping binding sites on
each TfR chain; thus, HFETfRFe-Tf ternary complexes have a
1:1:1 stoichiometry, such that HFE binds to one TfR polypep-
tide chain and Fe-Tf binds to the other.
Comparison of the crystal structures of TfR alone (27) and a
2:1 HFETfR complex (19) reveals that HFE binding induces
changes at the TfR dimer interface that are distant from the
HFE binding site, suggesting that HFE binding to one polypep-
tide chain of the TfR dimer can transmit structural changes to
the other TfR chain. These changes could influence the binding
of Fe-Tf or another HFE to the other side of the TfR dimer.
Indeed, in some studies, Fe-Tf binds with a lower apparent
affinity to cell surface TfR in the presence of membrane-bound
or soluble HFE (8, 21), and an affinity reduction is also ob-
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served when Fe-Tf binds to soluble TfR in the presence of
soluble HFE (23). The apparent affinity reduction could result
from competition between Fe-Tf and HFE for binding to TfR,
from negative cooperativity due to structural changes in the
unbound TfR chain that are imparted by HFE binding to the
other chain, or from a combination of both phenomena.
Investigation of the mechanism by which HFE influences the
binding of Fe-Tf to TfR is complicated, because complexes in
addition to the HFETfRFe-Tf ternary complex form in an
equilibrium mixture of the three proteins (Fig. 1). Thus, previ-
ous quantitative binding studies have derived equilibrium dis-
sociation constants (KD values) only for binary HFETfR and
Fe-TfTfR complexes (18, 20, 24, 28). Using Fe-Tf, a soluble
serum protein, and recombinant soluble forms of HFE and TfR,
we previously measured equilibrium dissociation constants (KD
values) for the first (KD1) and second (KD2) binding events to
homodimeric TfR, demonstrating that HFE binds with lower
affinity to TfR than does Fe-Tf (18, 20, 24) (Fig. 1). In this
study, we examine how binding of HFE or Fe-Tf to one side of
the TfR dimer affects binding to the other chain in the absence
of the competing binary complexes, using a heterodimeric form
of soluble TfR (hdTfR) in which one chain can bind HFE and
not Fe-Tf and the other chain can bind Fe-Tf but not HFE.
Using analytical ultracentrifugation (AUC) and surface plas-
mon resonance (SPR) binding assays, we verified that hdTfR
binds one HFE and one Fe-Tf. We then measured the affinity of
the free TfR chain for Fe-Tf (or HFE) when HFE (or Fe-Tf) is
bound to the other chain. We found no affinity reduction for
Fe-Tf or HFE binding to hdTfR in the presence of saturating
amounts of the other ligand, suggesting that direct competi-
tion, rather than negative cooperativity, is responsible for the
apparent affinity reduction in Fe-Tf binding to cell surface and
soluble TfR in the presence of HFE.
Having determined that HFE lowers the apparent affinity
for Fe-Tf by directly competing for TfR binding sites rather
than through an allosteric mechanism, we evaluated the effects
of this competition at physiological concentrations of Fe-Tf
using HFE and TfR expressed in transfected cells. We first
demonstrate that a green fluorescent protein (GFP)-tagged
form of HFE is dependent on its association with TfR for
transport to Tf-positive endosomal compartments. We then
show that the addition of Fe-Tf to the cellular media induces a
redistribution of HFE within the cells, suggesting that fluctu-
ations in serum Fe-Tf concentration can significantly alter the
stoichiometric ratios of the possible TfR complexes and free
proteins at the cell surface. These results are discussed in
terms of the role of HFE in the control of cellular iron
homeostasis.
EXPERIMENTAL PROCEDURES
Production of Wild-type Proteins—Soluble wtTfR was produced in a
lytic baculovirus/insect cell expression system as previously described
(18). Briefly, we used a modified version of the pAcGP67A expression
vector (Pharmingen) that codes for the gp67 hydrophobic leader se-
quence followed by a His6 tag, factor Xa cleavage site, and residues
121–760 of human TfR. Soluble human HFE/2-microglobulin het-
erodimers were expressed in Chinese hamster ovary cells and purified
as previously described (18). Human Fe-Tf was prepared from apo-Tf
(Sigma) by incubation with bicarbonate and excess ferric ammonium
sulfate.
Expression of hdTfR and Homodimeric TfR Mutants—Mutations
(L619A/Y643A for the Fe-Tf-binding TfR chain and Y123S/G647A/
R651A for the HFE-binding TfR chain) were introduced into the expres-
sion vector encoding human wtTfR (wild-type TfR) using the
QuikChangeTM protocol (Stratagene). Constructs were verified by se-
quencing of the protein-coding region. His-tagged mutant TfR ho-
modimers were expressed in baculovirus-infected insect cells and puri-
fied as described above. For production of hdTfR, the L619A/Y643-TfR
construct was mutagenized further to exchange the His6 tag for the
StrepTag II affinity tag (WSHPQEK) (29), a sequence designed to bind
to streptactin, a modified form of streptavidin (30). PCR was used to
introduce restriction sites and a ribosomal binding sequence (CCTATA-
AAT) immediately upstream of the start codon and to amplify the
coding regions of the L619A/Y643A-TfR and Y123S/G647A/R651A-TfR
constructs. The mutant TfR sequences were ligated into the pFastBac-
DUAL (Invitrogen) dicistronic baculovirus expression vector. The gene
encoding Y123S/G647A/R651A-TfR was ligated 3 to the p10 promoter
site using SphI and XhoI restriction sites, and the gene encoding
L619A/Y643A-TfR was ligated downstream of the polyhedron promoter
using BssHII and NotI restriction sites. Recombinant viruses were
generated by co-transfection of a transfer vector with linearized viral
DNA (Baculogold, Pharmingen) for TfR homodimers or by use of the
Bac-to-Bac® system (Invitrogen) for hdTfR.
Purification of hdTfR—Separation of the three species of TfR pro-
duced by insect cells expressing both mutant TfR chains (HFE-binding
homodimers, Fe-Tf-binding homodimers, and hdTfR) was achieved us-
ing sequential affinity chromatography steps. Infected insect cell su-
pernatants containing the secreted TfR species were concentrated and
exchanged into 50 mM Tris, pH 7.4, 300 mM NaCl, 10% glycerol, and 15
mM imidazole. Supernatants were passed over a Ni2-NTA Superflow
agarose column (Qiagen), and the two His-tagged species (Fe-Tf-bind-
ing homodimers and hdTfR) were eluted from the column with 250 mM
imidazole. The eluted peak was loaded onto a 15-ml streptactin-Sepha-
rose column (Sigma-Genosys). After washing with a buffer containing
50 mM PIPES, pH 7.4, and 150 mM NaCl, the column was eluted by the
addition of the same buffer with 3 mM desthiobiotin to obtain hdTfR.
The column was regenerated by the addition of 1 mM 4-hydroxyazoben-
zene-2-carboxylic acid, which was removed by washing the resin accord-
ing to the manufacturer’s instructions. Due to low levels of nonspecific
binding of the different TfRs to the Ni2-NTA and streptactin resins,
the columns were washed extensively after loading (20 column vol-
umes for Ni2-NTA superflow and 5 column volumes for streptactin
superflow), which eliminated homodimer carry-through. The purity of
hdTfR was monitored throughout the purification process by reverse-
phase fast protein liquid chromatography using a Resource Phe column
(Amersham Biosciences). (NH4)2SO4 was added to protein samples to a
concentration of 850 mM prior to loading on the column, and proteins
were eluted by a gradient from 850 to 0 mM (NH4)2SO4 over 20 column
volumes. The two contaminating homodimers resolve into well sepa-
rated peaks with the hdTfR appearing as a peak between them, as
verified by Western blotting using the anti-penta-His antibody (Qiagen)
and alkaline phosphatase-conjugated streptactin (IBA) (data not
shown). After elimination of detectable contaminating TfR homodimers,
hdTfR samples were passed over a Superdex-200 column (Amersham
Biosciences) to remove aggregates and exchanged into 50 mM PIPES,
pH 7.4, 150 mM NaCl, and 0.05% NaN3.
Circular Dichroism—CD spectra and thermal denaturation profiles
were obtained using an Aviv 62A DS spectrometer with a thermoelec-
FIG. 1. Equilibrium relationships for complexes formed by
HFE, Fe-Tf, and TfR. Statistically corrected equilibrium binding con-
stants are shown for binary binding reactions (Table I). N.D., KD values
determined for hdTfR but not wtTfR.
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tric cell holder and cuvette with a 1-mm path length. Measurements
were recorded using samples containing 5 M TfR protein in 20 mM
PIPES, pH 7.4, and 80 mM NaCl. Wavelength scans were collected from
200 to 250 nm in 1-nm increments. For thermal melts, the CD signal at
220 nm was recorded every 1 °C from 4 to 99 °C with an equilibration
time of 2 min and an averaging time of 1 min.
Biosensor Analyses—All biosensor experiments were carried out us-
ing a BIACORE 2000 instrument (Amersham Biosciences). Interactions
between a protein immobilized on the sensor chip (the “ligand”) and a
protein injected over the sensor surface (the “analyte”) are monitored in
real time as a change in surface plasmon resonance as measured in
resonance units (31, 32). Sensor chips were prepared using standard
primary amine coupling chemistry to attach 2000–4000 resonance
units of the anti-penta-His antibody (Qiagen) (BIACORE manual),
which was used to capture wtTfR and homodimeric TfR mutants (two
His tags) directly from insect cell supernatants as described (24). hdTfR
was covalently immobilized using primary amine chemistry (BIACORE
manual). In each experiment, one of the four flow cells of a CM5
biosensor chip (Amersham Biosciences) was mock-coupled with anti-
body but no TfR for use as a reference cell. Binding data were collected
as previously described (24).
Kinetic sensorgram data were pre-processed using Scrubber (Bio-
Logic Software Pty. Ltd.; available on the World Wide Web at www.bio-
logic.com.au), and kinetic constants were determined by simulta-
neously fitting the association and dissociation phases of all curves
using the Clamp99 program (33) to either a 1:1 model or a bivalent
ligand (2:1) model. The 1:1 model describes a simple bimolecular inter-
action and yields single association (kon) and dissociation (koff) values.
The bivalent ligand model describes the sequential binding of two
analyte molecules to a homodimeric ligand. This two-step process yields
apparent association (k1on,app, k2on,app) and dissociation (k1off,app,
k2off,app) values for each of the two reactions as follows,
A  TfR 7 A:TfR (rate constants: k1on, app and k1off, app)
REACTION 1
KD1, app  k1off, app/ k1on, app (Eq. 1)
A  A:TfR 7 A2:TfR (rate constants: k2on,app and k2off,app)
REACTION 2
KD2,app  k1off,app/k1on,app (Eq. 2)
where A represents either HFE or Fe-Tf. The apparent rate constants
can be converted to intrinsic rate constants (k1on, k2on, k1off, and k2off) by
applying statistical factors to account for the two potential binding sites
on a homodimeric TfR to which the first analyte molecule can bind and
the two sites on the fully bound TfR from which the first dissociation
event can occur. Thus, the intrinsic rate constants are related to the
apparent rate constants such that k1on  k1on,app/2 and k2off  k2off,app/2
for independent binding sites. Apparent and intrinsic rates and their
relative dissociation constants are reported in Table I to facilitate
comparison with our previous studies (20, 24).
To evaluate cooperativity in ligand binding, both hdTfR and wtTfR
were chemically coupled because of the requirement for base line sta-
bility over the period of 2 days. A concentration series of HFE or Fe-Tf
was injected to determine binding affinities in a buffer of 50 mM PIPES,
pH 7.4, 150 mM NaCl, 0.005% (v/v) surfactant P-20. The concentration
series was then repeated with the analyte diluted into a buffer to which
50 M Fe-Tf or 10 M HFE had been added. Equilibrium binding data
were collected and processed as previously described (24).
Analytical Ultracentrifugation—Sedimentation velocity experiments
were performed at 25 °C in a Beckman XL-I Ultima analytical ultra-
centrifuge using absorbance optics. Protein concentrations were deter-
mined spectrophotometrically at 280 nm using extinction coefficients of
187,199 M1 cm1 (wtTfR dimer), 190,230 M1 cm1 (hdTfR), 89,120 M1
cm1 (HFE/2-microglobulin), and 111,399 M
1 cm1 (Fe-Tf). The con-
centrations of wtTfR and hdTfR were fixed at 2.5 M for all experi-
ments. HFE and Fe-Tf were added at the indicated relative molar ratios
to TfR (see Fig. 4). Samples were brought to a final volume of 350–420
l and loaded into two-sector, charcoal-filled epon centerpieces with
quartz windows and placed in a four-hole An-60 titanium rotor. Sam-
ples were spun at 32,000, 34,000, or 36,000 rpm. Individual scans were
collected at 250 or 280 nm with a step size of 0.005 cm until samples
reached the bottom of the cell. Data were fit with the program SEDFIT
8.7 (34) using the c(s) analysis routine, which calculates the differential
distribution of sedimentation coefficients with an explicit treatment of
sample diffusion. The reported apparent sedimentation coefficients (s*)
values are not corrected to standard conditions because of difficulties
obtaining partial specific volumes of the glycosylated HFE, TfR, and
Fe-Tf proteins.
Generation of HFE-GFP-expressing TRVb and TRVb-1 Cells—PCR
was used to amplify the enhanced green fluorescent protein (EGFP)
gene in the pEGFP-1 vector (Clontech) to remove the start codon and
introduce a 5 in-frame XhoI site and 3 HindIII site. The modified gene
was subcloned into pBluescript II SK (Stratagene). PCR was used to
introduce a 5 Asp718 site and an in-frame 3 XhoI site at the 3-end of
the human HFE gene, which was then introduced into the EGFP
Bluescript vector. The resulting open reading frame encoded the entire
HFE amino acid sequence, a leucine-glutamate linker region, and
EGFP without its N-terminal methionine. The HFE-EGFP chimeric
gene was subcloned after sequencing into the mammalian cell expres-
sion vector pCB6-HindIII (gift of Ira Mellman, Yale University), which
carries a neomycin resistance gene for G418 selection (35).
TRVb and TRVb-1 cell lines were a generous gift from Dr. Timothy
McGraw (Cornell University) (36). Both cell lines were maintained in
Ham’s F-12 medium (Sigma) supplemented with 10% fetal bovine se-
rum, 2 mM glutamine, 12 mM glucose, and 400 g/ml G418 (TRVb-1 and
transfected cells only). Cells were grown to 90% confluence prior to
transfections, which were performed using the HFE-GFP expression
vector, a human 2-microglobulin expression vector (18), and the Lipo-
fectAMINE 2000 kit (Invitrogen) according to the manufacturer’s direc-
tions. Clones exhibiting green cell surface fluorescence were isolated
using limiting dilution 2 days after transfection. Cells were sorted for
GFP fluorescence using a Coulter Elite flow cytometer (Beckman
Coulter Inc.) to isolate cells with a medium level of GFP fluorescence.
Confocal Microscopy—Cells were dissociated using trypsin-free dis-
sociation buffer (Invitrogen), seeded onto glass coverslips in 6-well
plates, and grown to confluence. For redistribution experiments, the
culture medium was removed and replaced with medium containing
varying concentrations of human Fe-Tf (Sigma) or chicken iron-loaded
ovo-transferrin (Sigma), and cells were incubated at 37 °C in a 5% CO2
incubator for 1 h. The culture dishes were then placed on ice and
washed three times with ice-cold phosphate-buffered saline. Cells were
then fixed at 4 °C for 30 min in 4% paraformaldehyde in phosphate-
buffered saline, washed in cold phosphate-buffered saline, and mounted
on glass slides using Vecta Shield mounting media (Vector Laborato-
ries, Burlingame, CA). For Tf colocalization experiments, cells were
incubated for 1 h at 37 °C with 15 g/ml Alexa-546-conjugated human
Fe-Tf (Molecular Probes, Inc., Eugene, OR) in growth medium and
processed as above.
Cells were imaged on a Zeiss LSM Pascal Inverted confocal micro-
scope using a  63 oil immersion Apochromat objective (numerical
aperture 1.4). GFP was excited by the 488-nm line from an argon/
krypton laser, and Alexa-546-labeled human Fe-Tf was imaged using
the 543-nm line from a helium/neon laser. Two-color data were collected
in multitracking mode to prevent fluorophore cross-talk. Images were
collected and processed with a Zeiss LSM image examiner. Reported
images are 1-m sections collected 2–3 m above the basal side of the
cell.
RESULTS
Production of a Heterodimeric Transferrin Receptor—To con-
struct a TfR heterodimer (hdTfR) in which one chain only binds
HFE and the other chain only binds Fe-Tf, we first identified
mutations in human TfR homodimers that eliminate binding of
one TfR ligand while having a minimal effect on binding of the
other ligand. The choice of residues to substitute was compli-
cated by the fact that the HFE and Fe-Tf binding sites overlap
on the surface of TfR; thus, many residue substitutions that
reduce binding of one ligand also reduce binding of the other
(20, 24). We therefore sought to identify mutations that keep
the KD value for binding the desired ligand within the micro-
molar to nanomolar range while reducing the affinity for bind-
ing to the undesired ligand to a 10 M or higher KD. Our
choice of TfR substitutions was based on results from previous
measurements of the affinities of mutant TfRs for Fe-Tf and
HFE (24). To create a TfR chain that binds Fe-Tf but not HFE,
we combined substitutions L619A and Y643A, each of which
eliminates detectable HFE binding but has a more limited
effect on Fe-Tf binding (13- and 27.5-fold affinity reductions,
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respectively) (20, 24). To create a TfR mutant that binds HFE
but not Fe-Tf, we combined three substitutions: Y123S, G647A,
and R651A. Each of these mutations has a significant effect on
Fe-Tf binding (8.3-, 222-, and 2,800-fold affinity reductions,
respectively) (20, 24). Of these, only one substitution (G647A)
exhibits any measurable effect on HFE binding (2.6-fold affin-
ity reduction) (20, 24).
An hdTfR composed of one non-HFE binding and one non-
Fe-Tf binding chain was produced by co-expression of the two
mutant TfR chains in baculovirus-infected cells. To aid in pu-
rification, the Fe-Tf-binding TfR chain contained an N-termi-
nal StrepTagII sequence (29), and the HFE-binding TfR chain
contained a His6 tag. Expression in infected insect cells yields
three TfR dimers: HFE- but not Fe-Tf-binding homodimers,
Fe-Tf- but not HFE-binding homodimers, and hdTfR. Sequen-
tial passage of baculovirus supernatants over a Ni2-NTA col-
umn and a streptactin (30) column resulted in separation of
hdTfR from the mutant TfR homodimers and from other pro-
teins in the media. hdTfR appeared to be a stable species, since
we found no evidence of homodimers or monomers in hdTfR
samples stored for up to 2 months (data not shown). The far UV
CD spectra (Fig. 2A) and thermal denaturation (Fig. 2B) pro-
files of wtTfR and hdTfR showed no significant differences,
demonstrating that the mutations introduced into the hdTfR
do not adversely affect its folding or stability.
Binding Affinities of HFE and Fe-Tf to hdTfR and Ho-
modimeric TfR Mutants—Affinities of wtTfR and the mutant
TfRs were measured in an SPR-based assay for binding to a
soluble form of human HFE or to human Fe-Tf at pH 7.4 (18,
20, 24). Doubly His-tagged wtTfR and homodimeric TfR mu-
tants were captured on biosensor chips using a covalently
coupled anti-His tag antibody (20, 24), and the hdTfR was
chemically coupled using primary amine chemistry (see “Ex-
perimental Procedures”). Either HFE or Fe-Tf was then in-
jected over the TfR-coupled sensor chip. Binding data were fit
to a bivalent ligand model in which equilibrium dissociation
constants (KD1 and KD2) are derived for binding to the first and
the second binding sites on homodimeric wild-type and mutant
TfRs (Table I and Fig. 3) or to a 1:1 binding model in the case
of hdTfR. The Y123S/G647A/R651A mutant homodimer does
not detectably bind Fe-Tf at any tested concentration (up to 60
M) (Fig. 3B). Its binding affinity for HFE (Fig. 3A) was reduced
2.8-fold relative to wtTfR, consistent with the 2.6-fold reduction
observed for the G647A mutant in our previous studies (20, 24).
The slight affinity reduction resulted from an increased off-rate
compared with wtTfR (Table I). The L169A/Y643A mutant
homodimer exhibited no detectable binding to HFE (at concen-
trations up to 20 M) (Fig. 3C), and its affinity for Fe-Tf was
reduced 500-fold (Fig. 3D), again due to an increased off-rate
(Table I). We previously demonstrated that the loss in free
energy for binding Fe-Tf for the two single mutants that com-
pose the L619A/Y643A mutant is 1.5 kcal/mol (L619A) and 2.0
kcal/mol (Y643A), predicting a G value of 3.5 kcal/mol at
25 °C for the double mutant if the two substitutions act inde-
pendently (24). Consistent with this prediction, the observed
502-fold loss of binding affinity for the L169A/Y643A mutant
(Table I) corresponded to a G of 3.7 kcal/mol at 25 °C.
The binding data for the mutant TfR homodimers were then
compared with binding data for hdTfR. The better fit of the 1:1
binding model to binding reactions involving hdTfR (Fig. 3, G
and H) compared with wtTfR (Fig. 3, E and F, 1:1 model and
residuals) suggests that hdTfR forms 1:1 complexes with Fe-Tf
and with HFE. Analysis of the differences in derived binding
constants is complicated by the use of different binding models
for hdTfR or homodimeric TfRs: a 1:1 binding model for the
hdTfR yields a single value for the KD, whereas the bivalent
ligand model describing binding to the homodimeric TfRs
yields KD values describing the first and second binding events
(see “Experimental Procedures”). The derived KD values for the
HFE-binding and Fe-Tf-binding chains of the hdTfR are within
3-fold of statistically corrected KD1 values for their respective
homodimeric mutants (Table I), suggesting that hdTfR does not
have significantly altered binding affinities relative to the ho-
modimeric mutants from which it was derived.
Determination of Ligand-binding Stoichiometries of wtTfR
and hdTfR—To further compare the ligand-binding properties
of hdTfR and wtTfR, we used sedimentation velocity AUC.
Velocity AUC data were analyzed using the c(s) size distribu-
tion method in the program SEDFIT 8.7 (34). This method fits
the data numerically to the Lamm equation and yields a dif-
ferential distribution of s* values while explicitly correcting for
diffusion of the sedimenting species. The output is displayed as
a continuous distribution of s* values versus the c(s*) function
describing the distribution of molecular masses in solution.
We first determined the sedimentation properties of binary
HFETfR and Fe-TfTfR complexes. Each of the individual pro-
teins migrates as a single sharp peak when spun alone (Fig. 4,
dashed black lines labeled HFE, Fe-Tf, wtTfR, or hdTfR). Fig.
FIG. 2. Circular dichroism spectra and thermal denaturation profiles of wtTfR (pink triangles) and hdTfR (blue diamonds). A,
far-UV CD spectra of wtTfR and hdTfR. The measured CD signal is given as []r, the molar ellipticity per residue. Data points represent the average
and standard deviation of three (wtTfR) or five (hdTfR) replicate scans. B, comparison of thermal denaturation profiles for wtTfR and hdTfR. The
CD signal at 220 nm was monitored as a function of increasing temperature and plotted as fraction unfolded after normalization. The transition
midpoints derived from a plot of d[]r)/dT versus T are 64.8 °C for wtTfR and 65.0 °C for hdTfR.
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4A shows the results of mixing HFE and wtTfR in molar ratios
of 1:1, 2:1, 4:1, and 6:1, confirming previous findings of both 1:1
and 2:1 HFE/TfR complexes in solution (18, 20), with 2:1 being
the terminal stoichiometry as indicated by the presence of
excess HFE at the higher mixing ratios. By contrast, mixing
excess HFE in the presence of hdTfR resulted in a peak corre-
sponding to a 1:1 HFETfR complex, confirming that hdTfR
does not readily form 2:1 HFETfR complexes (Fig. 4D). Anal-
ogous experiments were performed to investigate binary inter-
actions of Fe-Tf with wtTfR and hdTfR. Fig. 4B shows the
results of mixing Fe-Tf and wtTfR at various ratios, confirming
previous reports of a 2:1 terminal Fe-Tf/TfR stoichiometry (17,
18). Here we note evidence for formation of a 1:1 Fe-TfTfR
complex at the 1:1 mixing ratio, which, although predicted to be
present in an equilibrium mixture of Fe-Tf and TfR (Fig. 1), has
not been previously reported. Mixing Fe-Tf with hdTfR re-
sulted in two connected peaks in the c(s*) distribution (Fig. 4E).
The smaller peak represents free hdTfR, and the larger peak is
due to the 1:1 Fe-TfhdTfR complex. The slightly different po-
sition for the 1:1 Fe-TfhdTfR peak compared with the position
for the 1:1 Fe-TfwtTfR peak results from the faster kinetics of
complex association and dissociation for hdTfR compared
with wtTfR (Table I). We see no evidence of a 2:1 Fe-TfhdTfR
complex (Fig. 4E).
We next used sedimentation velocity AUC to characterize
the complexes formed when hdTfR and wtTfR are mixed with
both HFE and Fe-Tf. At a mixing ratio of 1:1:1 HFE/wtTfR/Fe-
Tf, a broad peak centered at 11.8 S was observed (Fig. 4C). The
TABLE I
HFE and Fe-Tf binding to TfR constructs at 25 °C
Kinetic and equilibrium constants derived from fitting of the surface plasmon resonance data shown in Fig. 3. Numbers in parentheses are
corrected for statistical factors (see ‘‘Experimental Procedures’’). NB, no binding detected at concentrations of injected analyte up to 80 M Fe-Tf
or 20 M HFE.
Ligand (immobilized protein)
Analyte
(injected
protein)
kon1 koff1 kon2 koff2 KD1 KD2
KD1, KD2
(relative
to wild
type)
Ms1 s1 Ms1 s1 nM nM
wtTfR HFE 3.7  106 (1.8  106) 0.09 2.6  106 0.37 (0.20) 24 (48) 154 (77)
wtTfR Fe-Tf 1.7  106 (8.3  105) 1.0  103 1.6  105 5.8  103 (3.2  103) 0.6 (1.3) 40.6 (20.3) 2.8, 2.5
Y123S/G647A/R651A-TfR HFE 3.6  105 (1.8  106) 0.25 2.2106 0.82 (0.41) 67 (134) 384 (192)
Y123S/G647A/R651A-TfR Fe-Tf NB NB 27,000
L619A/Y643A-TfR HFE NB NB 800
L619A/Y643A-TfR Fe-Tf 5.2  105 (2.4  105) 0.15 1.5  105 0.46 (0.23) 314 (627) 2,940 (1,470) 502, 73
hdTfR HFE 6.8  105 0.27 390 8.1
hdTfR Fe-Tf 1.9  105 0.23 1,210 930
FIG. 3. SPR analysis of HFE and
Fe-Tf binding to TfR proteins. Exper-
imentally observed response (black lines)
of HFE or Fe-Tf binding to the indicated
TfR molecules is shown with superim-
posed best fit binding curves (colored
lines) derived from a bivalent ligand bind-
ing model (wtTfR and homodimeric mu-
tant TfRs except where noted) or a 1:1
binding model (hdTfR). Residual plots
(difference between the observed and cal-
culated binding data) are shown in E–H
below the response data. The wtTfR bind-
ing data shows fits and residuals for both
1:1 (green) and bivalent ligand (red) bind-
ing models. The highest concentrations in
the injection series for each sensorgram
are 5 M (A), 60 M (B), 20 M (C), 6 M
(D), 2 M (E), 111 nM (F), 1.6 M (G), and
10 M (H). Subsequent injections are re-
lated by 3-fold dilutions.
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location of the center of the peak midway between the peaks for
the 2:1 HFEwtTfR and 2:1 Fe-TfwtTfR complexes and the fact
that the peak spans the positions of the binary complexes are
consistent with identification of this peak as a mixture of the
1:1:1 HFETfRFe-Tf ternary complex with binary 2:1 Fe-TfTfR
and 2:1 HFETfR complexes (Fig. 4C, red curve). Mixing of the
three proteins at higher ligand ratios (2:1:2 and 3:1:3 HFE/TfR/
Fe-Tf) resulted in a peak closer to the one observed for 2:1
Fe-Tf/TfR, demonstrating that Fe-Tf effectively competes HFE
away from TfR in solution, due to the intrinsically higher TfR
binding affinity of Fe-Tf compared with soluble HFE. Mixing of
HFE and Fe-Tf with the hdTfR also resulted in a peak between
the 2:1 HFEwtTfR and 2:1 Fe-TfwtTfR complexes (Fig. 4F).
The distribution was more narrow for the ternary complex
involving hdTfR, consistent with the expectation that binary
complexes with a 2:1 ligand/hdTfR stoichiometry do not form.
Comparison of HFE and Fe-Tf Binding to hdTfR and wtTfR
Rules Out Cooperativity in Ligand Binding—Having demon-
strated that the engineered hdTfR binds to one HFE and one
Fe-Tf to form a ternary complex, we could use the hdTfR to
evaluate the potential for heterotropic cooperativity in ligand
binding in the absence of the competition observed when using
wtTfR. Cooperativity in binding was assessed using an SPR-
based binding assay to compare the binding behavior for either
HFE or Fe-Tf to hdTfR in the presence and absence of excess
Fe-Tf or HFE. If cooperativity is a feature of TfR interactions
with HFE or Fe-Tf, then incubation of TfR with saturating
amounts of one ligand will perturb the equilibrium binding
curve of the second ligand. For these experiments, wtTfR and
hdTfR were immobilized on adjacent flow cells of the same
sensor chip using primary amine coupling chemistry. We then
evaluated the binding of HFE to each TfR in the presence and
absence of a saturating concentration of Fe-Tf (50 M). Binding
data were collected using an equilibrium-based approach in
which binding reactions reached or closely approached equilib-
rium. Data for HFE binding to hdTfR in the presence and
absence of Fe-Tf (Fig. 5B) showed no significant differences,
indicating that binding of Fe-Tf to one chain of TfR does not
alter the binding properties of the other chain for HFE. Simi-
larly, the binding of Fe-Tf for hdTfR was not altered by the
presence of a saturating amount of HFE (10 M) (Fig. 5D). By
contrast, when the same binding experiments were performed
with wtTfR, we observed competition between HFE and Fe-Tf
for binding to TfR. When HFE was injected in the presence of
FIG. 4. Stoichiometries of HFE and Fe-Tf binding to wtTfR and hdTfR from sedimentation velocity ultracentrifugation. The c(s*)
distribution was determined for each protein alone or in the mixing ratio indicated to the right of each panel. Reference curves for individual
proteins or specific complexes are shown as dotted black lines. Peak heights were normalized to the height of the species with the largest s* value
in the distribution.
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excess (50 M) or near physiological (5 M) (37) quantities of
Fe-Tf (Fig. 5A), only a small amount of HFE binding was
observed at the highest concentrations tested (Fig. 5A). This
binding was observed as a decrease in SPR signal, because the
binding of HFE requires the displacement of Fe-Tf, which is 1.8
times heavier than HFE, from its binding site on TfR (20, 24,
25). When Fe-Tf was injected in the presence of saturating
amounts of HFE (10 M), there was a reduction in Fe-Tf bind-
ing (Fig. 5C), consistent with previous reports that HFE re-
duces the observed binding affinity of Fe-Tf to TfR (8, 21, 23).
Consistent with the lower TfR binding affinity of HFE as com-
pared with Fe-Tf, HFE begins to compete with Fe-Tf for bind-
ing wtTfR only when it is present at a 4-fold or higher concen-
tration than Fe-Tf, whereas Fe-Tf begins to compete with HFE
for binding wtTfR when it is present at one-tenth the concen-
tration of HFE. Taken together, these experiments confirm
that HFE and Fe-Tf compete for TfR binding sites and rule out
the effects of negative cooperativity in the HFE/hdTfR/Fe-Tf
ternary interaction.
Cell Surface HFE Competes Effectively with Fe-Tf for Bind-
ing to Cell Surface TfR—The demonstration that negative co-
operativity is not involved in heterotropic interactions between
TfR, HFE, and Fe-Tf indicates that direct competition between
HFE and Fe-Tf for binding to cell surface TfR is solely respon-
sible for the observation that HFE lowers the affinity of TfR for
Fe-Tf (5, 21, 23). Our SPR and AUC experiments demonstrate
that soluble HFE competes poorly against Fe-Tf for TfR bind-
ing because of its lower affinity for TfR compared with Fe-Tf
(Figs. 4C and 5A). Under physiological conditions, however,
HFE and TfR are tethered to the same membrane (19), thereby
increasing their effective local concentrations and permitting
potential interactions between the HFE and TfR cytoplasmic
tails (22). Either or both of these effects could allow HFE to
compete more effectively against Fe-Tf for binding to TfR.
To evaluate how the addition of Fe-Tf affects complex forma-
tion between full-length HFE and TfR proteins tethered to a
common membrane, we first showed that binding to TfR is
required for a GFP-tagged form of HFE to traffic to Tf-positive
endosomal compartments, and then asked if the addition of
Fe-Tf affects endosomal localization of HFE-GFP. For these
experiments, we expressed an HFE-GFP chimeric protein, in
which GFP was fused to the C terminus of full-length HFE, in
two forms of Chinese hamster ovary cells: TRVb cells, which
lack expression of endogenous hamster TfR, and TRVb-1 cells,
which lack endogenous TfR but stably express human TfR (36).
Confocal imaging of HFE-GFP-expressing TRVb-1 (HFE/
TfR) cells reveals primarily intracellular fluorescence (Fig.
6A, middle panel), which co-localizes with endocytosed Alexa-
546-labeled human Fe-Tf (Fig. 6A, right panel), demonstrating
that the HFE traffics to Tf-positive endosomes in cells express-
ing TfR. By contrast, most of the GFP fluorescence in HFE-
GFP-expressing TRVb cells (HFE/TfR) was primarily local-
ized at the cell surface (Fig. 6A, left panel), and these cells show
no significant intracellular fluorescence in Alexa-546 Fe-Tf up-
take experiments (data not shown). These data demonstrate
that binding to cell surface TfR is required for HFE localization
in Tf-positive endosomes, consistent with the lack of an obvious
endocytic signal in the HFE cytoplasmic tail (3, 8, 21). Thus,
endosomal localization of HFE-GFP can be used to evaluate
competition between Fe-Tf and HFE for binding to cell surface
TfR.
Since HFE binding to TfR is required for HFE translocation
to Tf-positive endosomes, we investigated whether endosomal
localization of HFE could be prevented by the presence of high
concentrations of extracellular Fe-Tf. To address this question,
we incubated TRVb-1-HFE-GFP (HFE/TfR) cells in growth
medium supplemented with Fe-Tf at concentrations ranging
from 0 nM to 50 M. At relatively low concentrations of extra-
cellular Fe-Tf (500 nM), HFE-GFP fluorescence began to redis-
tribute from intracellular locations to the cell surface (Fig. 6B).
Upon the addition of micromolar concentrations of Fe-Tf corre-
sponding to serum Fe-Tf levels (37), we saw a substantial
reduction of endosomal GFP fluorescence with a concomitant
increase in cell surface fluorescence (Fig. 6B). At Fe-Tf concen-
trations exceeding 5 M, little or no HFE-GFP fluorescence
localized to endosomes, indicating that Fe-Tf has competed
effectively with HFE to occupy virtually all binding sites on cell
surface TfR molecules (Fig. 6B). The addition of the same
concentrations of iron-loaded ovotransferrin, a transferrin or-
tholog that does not bind human TfR (38), did not result in
detectable redistribution of HFE-GFP from endosomal com-
partments to the cell surface (Fig. 6C), indicating that the HFE
FIG. 5. SPR assay of competition between HFE and Fe-Tf for binding to wtTfR versus hdTfR. Plots are of the normalized equilibrium
biosensor response value versus the log of the indicated protein concentration. HFE binding in the absence (blue diamonds) or presence of Fe-Tf
(50 M Fe-Tf (red square) and 5 M Fe-T (cyan triangle)) to wtTfR (A) or to hdTfR (B). Fe-Tf binding is shown in the absence (green circle) or presence
of 10 M HFE (magenta square) to wtTfR (C) or to hdTfR (D). Data points are related by a 1.6-fold dilution series.
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redistribution effect is due to direct competition between HFE
and human Fe-Tf for TfR binding sites.
DISCUSSION
TfR is a homodimeric receptor that binds two ligands at
neutral or basic pH: Fe-Tf and HFE. TfR can form binary
complexes with either HFE or Fe-Tf and can bind both ligands
simultaneously to form a 1:1:1 HFETfRFe-Tf ternary complex
(18–20). Characterizing the ternary complex is of interest,
because both soluble and membrane-bound HFE reduce the
apparent affinity of soluble and membrane-bound TfR for Fe-Tf
(8, 21, 23, 39). Since mixtures of binary and ternary complexes
form when all three proteins are present (Fig. 1), it has not
been possible to determine if HFE reduces the affinity of TfR
for Fe-Tf via direct competition for overlapping binding sites on
TfR and/or if structural changes induced by HFE binding to one
chain of the TfR dimer (19) lowers the binding affinity for
ligand on the other TfR chain. Although several studies have
demonstrated that HFE and Fe-Tf compete for binding to a
common site on TfR (20, 24, 25), the potential role for negative
cooperativity in the binding of Fe-Tf to 1:1 HFETfR complexes
has not been addressed because of complications arising from
the competing side reactions that lead to 2:1 HFETfR and
Fe-TfTfR complexes when both HFE and Fe-Tf are incubated
with homodimeric wtTfR. To directly evaluate the effects of
heterotropic ligand binding to TfR, we constructed a hdTfR in
which one chain binds HFE but not Fe-Tf and the other chain
binds Fe-Tf but not HFE, such that only ternary complexes can
form when hdTfR is incubated with Fe-Tf and HFE.
FIG. 6. Confocal images of HFE-
GFP distribution in TRVb (TfR) and
TRVb-1 (TfR) cells. A, cells expressing
HFE-GFP (green fluorescence) in the ab-
sence (left) or presence (middle) of co-ex-
pressed human TfR. Co-localization of
HFE-GFP fluorescence with Alexa-546-
labeled human Fe-Tf in TfR cells is
shown on the right. B, cells expressing
HFE-GFP and human TfR incubated with
the indicated concentrations of unlabeled
human Fe-Tf in the culture media. C, cells
expressing HFE-GFP and TfR incubated
with the indicated concentrations of
chicken Fe-Tf (Fe-oTf) in the culture
media.
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Although many substitutions in the TfR ligand-binding site
affect binding to both ligands (20, 24), we were able to produce
an hdTfR in which the HFE-binding chain retains a 390 nM
affinity for HFE, but no detectable affinity for Fe-Tf, and the
Fe-Tf-binding chain retains a 1.2 M affinity for Fe-Tf but does
not bind detectably to HFE (Fig. 3, A–D, Table I). Sedimenta-
tion velocity AUC and biosensor binding assays demonstrate
that the hdTfR binds only one HFE and only one Fe-Tf and that
it forms a 1:1:1 HFETfRFe-Tf ternary complex when all three
proteins are mixed together. Having confirmed that hdTfR does
not participate in side reactions leading to binary complexes
(Fig. 1), we used it to evaluate whether binding of ligand to one
chain of TfR affects the binding affinity of the other ligand for
TfR. Biosensor binding assays conducted in the presence and
absence of a saturating concentration of Fe-Tf reveal no signif-
icant differences in the binding affinity of HFE for hdTfR.
Similarly, Fe-Tf binding to hdTfR is not altered by prebinding
HFE to one chain of hdTfR. By contrast, when wtTfR is incu-
bated with a saturating amount of HFE, we observe a reduction
in the apparent binding affinity for Fe-Tf, as previously re-
ported (23). The experiments using hdTfR demonstrate that
there is no cooperativity, either negative or positive, in hetero-
tropic ligand binding by hdTfR, suggesting that the apparent
lowering of the Fe-Tf affinity of cell surface and soluble wtTfR
by HFE (8, 23, 39, 40) results entirely from competition be-
tween HFE and Fe-Tf for overlapping binding sites on the TfR
surface. Extending these results to wtTfR requires the assump-
tion that the mutations used to create the hdTfR do not them-
selves disrupt cooperativity. Because we cannot evaluate coop-
erativity using wtTfR, we cannot directly address this issue.
However, it is unlikely that the mutations themselves disrupt
cooperativity, because the substituted residues are on the ex-
terior of the protein in locations that are distant from the TfR
dimer interface, across which structural changes would need to
be propagated for cooperativity in ligand binding to occur.
Having shown that direct competition rather than allostery
affects heterotropic ligand binding by TfR in solution, we next
evaluated the effects of competition as a function of ligand
concentration. Using wtTfR in a biosensor-based binding assay,
we find that HFE shows only minimal binding to wtTfR when
Fe-Tf is present at concentrations of 5 M and above, demon-
strating that it can compete with Fe-Tf, but only when it is
several times more concentrated. Consistent with this result,
sedimentation velocity AUC experiments show that 2:1 Fe-
TfTfR complexes are the dominant species when HFE, Fe-Tf,
and wtTfR are mixed such that the HFE and Fe-Tf are at
higher concentrations than wtTfR. Therefore, soluble HFE is a
poor competitor for binding to soluble TfR when Fe-Tf is pres-
ent at high concentrations, including the micromolar concen-
trations corresponding to physiological levels of Fe-Tf in blood
(37).
If TfR binding is required for HFE to act as a regulator of
cellular iron homeostasis, then it must compete effectively
against physiological levels of Fe-Tf when TfR and HFE are
both present at the surface of a cell. Since HFE and TfR are
tethered to the same cellular membrane (19), the effective
concentrations of both proteins may be much higher than in the
biochemical assays involving soluble proteins used here. We
therefore developed a cell-based assay to evaluate the effects of
the addition of soluble Fe-Tf on the interaction between mem-
brane-bound HFE and membrane-bound TfR. As an indication
of HFETfR complex formation, we monitored the localization
of an HFE-GFP chimeric protein in transfected cells, assuming
that HFE-GFP fluorescence in endosomes represents HFE-
GFP that trafficked there as a result of binding to cell surface
TfR. This assumption was verified by showing that HFE traf-
ficks to Tf-positive endosomes in TfR-positive but not TfR-
negative cells; thus, TfR binding is required for HFE to enter
endosomes. By incubating the TfR-positive cells with Fe-Tf, we
then demonstrated a loss of endosomal HFE-GFP fluorescence
at relatively low concentrations of exogenous Fe-Tf (500 nM),
with a substantial redistribution of GFP fluorescence to the cell
surface at near physiological concentrations of exogenous Fe-Tf
(micromolar) (37). Thus, external levels of Fe-Tf can influence
both the localization and binding state of HFE in cells. The
relatively high concentrations of Fe-Tf required to affect HFE
localization and binding to TfR suggest a reevaluation of pre-
vious studies using transfected cells in which subphysiological
concentrations of Fe-Tf were used as the iron source (7, 21, 22,
39–44). Our data suggest that redistribution of HFE at micro-
molar concentrations of Fe-Tf in blood has functional conse-
quences that may not be observed in studies using submicro-
molar levels of Fe-Tf.
Indeed, competition between HFE and Fe-Tf for binding to
TfR has been hypothesized to be critical for controlling iron
metabolism (45, 46). In one model involving HFE/Fe-Tf compe-
tition, the concentration of Fe-Tf controls whether HFE binds
to TfR, thereby inhibiting uptake of Fe-Tf, or if HFE binds to
another cell surface protein (e.g. ferroportin, an iron-export
protein (47–49)), thereby inhibiting export of intracellular iron.
Although our results show that soluble HFE competes poorly
with Fe-Tf for binding to soluble TfR, membrane-bound HFE
can compete effectively with physiological concentrations of
exogenous Fe-Tf for binding to cell surface TfR. Thus, the
amount of cell surface HFE bound to cell surface TfR can be
controlled by the concentration of exogenous Fe-Tf, alone or in
concert with changes in TfR expression levels, allowing regu-
lation of the binding configuration of HFE at the cell surface.
There are three possible binding configurations of HFE at the
cell surface (bound to TfR, bound to another protein(s), or free),
each of which could be involved in regulation of iron homeosta-
sis. For example, HFE bound to TfR can prevent uptake of iron
in the form of Fe-Tf. If Fe-Tf binding to TfR competes away
HFE, allowing it to bind to an iron transport protein such as
ferroportin or DMT1 (an iron import protein (50)), then fluctu-
ations in the level of free versus bound HFE could regulate
either the rate of cellular iron export (ferroportin) or import
(DMT1). Additionally, if cells can sense the amount of cell
surface or endosomally localized HFE, then fluctuations in
those levels could affect downstream signaling.
Elucidating the details of the interactions between HFE,
TfR, and Fe-Tf will be critical for understanding the mecha-
nisms by which mammals regulate iron levels. We have clari-
fied the interactions between these proteins, demonstrating
that several TfR/ligand stoichiometries are possible, that HFE/
TfR binding is required for HFE transport to endosomes, and
that there is strong allostery-free competition between HFE and
Fe-Tf for TfR binding at the cell surface. These results provide
experimental support for models of iron regulation in which
competition between HFE and Fe-Tf for binding to TfR plays a
central role in maintaining cellular iron homeostasis (45).
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